Market Overview

Analyst: Insulet On Track For Profitability In 2018

Share:
Analyst: Insulet On Track For Profitability In 2018
Related PODD
Once Again, Baird Predicts End To Tandem's 'Fantastic' Run
The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet

Insulet Corporation (NASDAQ: PODD) is up 80.5 percent year-over-year, and even last quarter’s bottom-line miss can’t deter the biotech’s bulls.

The Rating

BMO Capital Markets analyst Joanne Wuensch initiated coverage of Insulet Corp. with an Outperform rating and $90 price target.

The Thesis

Wuensch anticipates a turn to profitability in the second half of 2018, with a series of catalysts sustaining positive performance.

Over the next two years, Insulet is expected to profit from the rollout of the OmniPod Dash platform and Horizon Automated Glucose Control System; a push for international direct sales; penetration of the U.S. Medicare market; approved distribution of higher concentration insulin; and expansion in Type 2 diabetes, the analyst said. 

At the same time, its Omnipod product is positioned to expand in an “underpenetrated” insulin pump market and capture the share abandoned by Roche and Johnson & Johnson (NYSE: JNJ), Wuensch said. The analyst said she expects a three-year share expansion from 15.2 percent to 22.1 percent.

“Insulet is on the right side of care with its OmniPod Pump, providing an easier, more efficacious means of insulin delivery without the obstacles of traditional pumps or multiple daily injections,” she said in a Monday note. 

Price Action

Insulet shares were up 2.31 percent at $77.57 in midday trading Tuesday. 

Related Links:

7 Biotech Stocks With Clinical Trial Outcomes In March

Pharma M&A Picks Up Momentum

Latest Ratings for PODD

DateFirmActionFromTo
Jun 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
May 2018Canaccord GenuityMaintainsBuyBuy
May 2018BMO CapitalMaintainsOutperformOutperform

View More Analyst Ratings for PODD
View the Latest Analyst Ratings

Posted-In: BMO Capital Markets Joanne WuenschAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga

 

Related Articles (PODD + JNJ)

View Comments and Join the Discussion!

Investor Movement Index February Summary

Becton Dickinson Has A Strong, Diverse Pipeline, But Is Fairly Valued, Says BMO